Viewing Study NCT04184050


Ignite Creation Date: 2025-12-24 @ 5:24 PM
Ignite Modification Date: 2025-12-25 @ 2:59 PM
Study NCT ID: NCT04184050
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-05
First Post: 2019-11-27
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module